Cargando…

Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain

The epidermal growth factor receptor (EGFR) gene encodes four alternatively spliced mRNA, variants 1, 2, 3 and 4, respectively, encoding the whole isoform a (EGFR) and truncated isoforms b, c and d, all of which lack the receptor’s intracellular domain. In addition, a mutant EGFRvIII differs from is...

Descripción completa

Detalles Bibliográficos
Autores principales:	GUILLAUDEAU, ANGÉLIQUE, DURAND, KARINE, RABINOVITCH-CHABLE, HÉLÈNE, POMMEPUY, ISABELLE, MESTUROUX, LAURA, ROBERT, SANDRINE, CHAUNAVEL, ALAIN, MOREAU, JEAN-JACQUES, LABROUSSE, FRANÇOIS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680776/ https://www.ncbi.nlm.nih.gov/pubmed/22159595 http://dx.doi.org/10.3892/ijo.2011.1287

Ejemplares similares

EGFR Soluble Isoforms and Their Transcripts Are Expressed in Meningiomas
por: Guillaudeau, Angélique, et al.
Publicado: (2012)

CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma
por: Deluche, Elise, et al.
Publicado: (2019)

Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
por: Bounaix Morand du Puch, Christophe, et al.
Publicado: (2016)

The Quantitative Analysis of bFGF and VEGF by ELISA in Human Meningiomas
por: Denizot, Yves, et al.
Publicado: (2006)

POFUT1 as a Promising Novel Biomarker of Colorectal Cancer
por: Chabanais, Julien, et al.
Publicado: (2018)

Analysis of Several PLA(2) mRNA in Human Meningiomas
por: Denizot, Yves, et al.
Publicado: (2009)

Detection of human cytomegalovirus genome and gene products in central nervous system tumours
por: Sabatier, J, et al.
Publicado: (2005)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Effect of Expression of Nuclear-Encoded Cytochrome C Oxidase Subunit 4 Isoforms on Metabolic Profiles of Glioma Cells
por: Oliva, Claudia R., et al.
Publicado: (2022)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Lack of cytomegalovirus detection in human glioma
por: Garcia-Martinez, Araceli, et al.
Publicado: (2017)

Protein tyrosine phosphatases in glioma biology
por: Navis, Anna C., et al.
Publicado: (2009)

PTPRR Protein Tyrosine Phosphatase Isoforms and Locomotion of Vesicles and Mice
por: Hendriks, Wiljan J. A. J., et al.
Publicado: (2009)

EGFR isoforms and gene regulation in human endometrial cancer cells
por: Albitar, Lina, et al.
Publicado: (2010)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

Differential Signature of the Centrosomal MARK4 Isoforms in Glioma
por: Magnani, Ivana, et al.
Publicado: (2011)

Antagonistic role of GSK3 isoforms in glioma survival
por: Vashishtha, Vidhi, et al.
Publicado: (2018)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Mechanisms of autoimmunity in mice lacking the mer membrane tyrosine kinase
por: Cohen, PL, et al.
Publicado: (2004)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma
por: Yue, Chenglong, et al.
Publicado: (2017)

Genetically encoded live-cell sensor for tyrosinated microtubules
por: Kesarwani, Shubham, et al.
Publicado: (2020)

Updated Insights on EGFR Signaling Pathways in Glioma
por: Oprita, Alexandru, et al.
Publicado: (2021)

Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the expression of EGFR isoforms A and D
por: Dhamodharan, Shankar, et al.
Publicado: (2021)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
por: Imamura, Fumio, et al.
Publicado: (2016)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
por: Zhang, Xuedi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sd4rh762gmflj0elrjbrl87p3q